Norges Bank bought a new position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 147,823 shares of the biopharmaceutical company's stock, valued at approximately $3,397,000. Norges Bank owned 0.21% of Xencor at the end of the most recent quarter.
A number of other large investors have also modified their holdings of the business. GAMMA Investing LLC grew its holdings in Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 508 shares during the period. KBC Group NV grew its position in Xencor by 26.0% during the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock worth $90,000 after buying an additional 813 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Xencor by 49.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company's stock valued at $93,000 after acquiring an additional 1,337 shares during the period. Sanctuary Advisors LLC boosted its stake in shares of Xencor by 5.3% during the 4th quarter. Sanctuary Advisors LLC now owns 28,263 shares of the biopharmaceutical company's stock worth $649,000 after acquiring an additional 1,432 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in shares of Xencor by 13.0% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,940 shares of the biopharmaceutical company's stock worth $343,000 after acquiring an additional 1,723 shares during the period.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on XNCR shares. StockNews.com lowered Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Wells Fargo & Company decreased their price target on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Xencor has a consensus rating of "Moderate Buy" and an average price target of $34.38.
Read Our Latest Analysis on Xencor
Xencor Stock Down 3.0 %
NASDAQ:XNCR traded down $0.29 during trading hours on Wednesday, hitting $9.26. The stock had a trading volume of 51,390 shares, compared to its average volume of 616,611. The business has a 50 day simple moving average of $12.75 and a two-hundred day simple moving average of $18.94. Xencor, Inc. has a 1-year low of $7.16 and a 1-year high of $27.24. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The company has a market cap of $652.13 million, a PE ratio of -2.89 and a beta of 0.90.
Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm had revenue of $52.79 million during the quarter, compared to analyst estimates of $17.14 million. Analysts predict that Xencor, Inc. will post -3.68 EPS for the current year.
About Xencor
(
Free Report)
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Further Reading
Before you consider Xencor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.
While Xencor currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
